| Filed On | Filing |
|---|---|
| 13 Nov 2026 | QUARTERLY REPORT |
| 07 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of October 6, 2026, is made by and among CERo Therapeutics Holdings, Inc., a Delaware corporation (“Seller”), and SRX Global Inc., a Delaware corporation formerly known as SRX He... |
| 31 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT... |
| 14 Aug 2026 | PROSPECTUS SUPPLEMENT |
| 14 Aug 2026 | QUARTERLY REPORT |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 17 Jul 2026 | PROSPECTUS SUPPLEMENT |
| 17 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 13 Jul 2026 | 25-NSE |
| 26 Jun 2026 | PROSPECTUS SUPPLEMENT |
| 26 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 29 May 2026 | PROSPECTUS SUPPLEMENT |
| 29 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Healt... |
| 15 May 2026 | PROSPECTUS SUPPLEMENT |
| 15 May 2026 | QUARTERLY REPORT |
| 01 May 2026 | PROSPECTUS SUPPLEMENT |
| 01 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keysto... |
| 01 May 2026 | PROSPECTUS SUPPLEMENT |
| 30 Apr 2026 | AMENDMENT NO. 1 TO FORM 10-K |
| 21 Apr 2026 |
Form 4: Francois Eric, Director
Granted 1,823,278 Stock Option (Right to Buy) |
Loading...